DOCSLIB.ORG

PHARMACEUTICALS + Biovian Oy Jemedic AB Bayer Oy + Shetland Bergen Helse Bergen HF, Haukeland 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PHARMACEUTICALS + Biovian Oy Jemedic AB Bayer Oy + Shetland Bergen Helse Bergen HF, Haukeland 3 BARENTS SEA Jan Mayen (Norway) Tromsø NORWAY Murmansk DENMARK STRAIT NORWEGIAN SEA Raufarhöfn Bolungarvik Kalix Aromtech Oy Mosjøen SWEDEN Kemi Akureyri Luleå WHITE SEA Piteå Eskifjördur Oy Woikoski Ab + Pharmatory Ltd + Bioactive Bone Substitutes Oolu Fermion Oy Olafsvik ICELAND Skellefteå IA Hornafjördur Reykjavik 1-5 Grindavik Apotek Produktion & Laboratorier AB Oy Woikoski Ab Umeå Norrlands Universitetssjukhus Frøya Vik Trondheim Kristiansund GULF OF BOTHN Vaasa Averøya Galena Pharma Oy + Orion Oyj + Finvector Oy Sandøy Härnösand Ålesund Sundsvall Unimedic AB + MAP Medical Technologies Oy Woikoski Ab Kristinestad Tórshavn Apoteksverkiö, Framleiösluapotekiö Måløy EWOS AS Santen Oy Cytomed Oy SWEDEN - Not Shown Vitabalans Oy + Umeå + Curida AS Apotek Produktion & Laboratorier AB Oy Aga Ab Norrlands Universitetssjukhus Jemedic AB FINLAND OSLO Gävle Alby Vyborg + Nouryon Pulp & Performance Chemicals AB Hankintatukku Oy 1. Smerud Medical Research Norway AS Pcas Finland Oy Finex Oy Hamina Orion Corporation Oy Woikoski Ab 2. Catapult Life Science AS Gävle + + EUROPE - PHARMACEUTICALS + Biovian Oy Jemedic AB Bayer Oy + Shetland Bergen Helse Bergen HF, Haukeland 3. PhotoCure ASA Turku Orion Corporation A.Vogel Oy universitetssjukehus 4. GE Healthcare AS Vitabalans Oy MAP Medicals Technologies Oy + Nanoform Finland Oy Islands 5. Oncoinvent AS Fermion Oy AGA Gas AB Lumene Oy Lerwick 6. The Cyclotron Center Pharmaq AS + Scan Aqua AS Orion Corporation + 7. Oslo Universitetssykehus HF HELSINKI 8. Diatec Monoclonals AS Institute for Energy Technology + Bayer (IFE) AMO Uppsala AB Q-Med AB Orexo AB Takeda AS Oasmia Pharmaceutical AB GULF OF FINLAND + Fresnius-Kabi (Uppsala) St. Peterburg Major Manufacturing Sites OSLO + Fermion Oy SWEDEN + + Nouryon Pulp and Performance + Alliance Healthcare PET-centrum, Akademiska sjukhuset Recipharm Uppsala AB Chemicals Norway AS FINLAND - Not Shown Hanko Kiviranta Aromtech Oy Oolu Fresnius-Kabi (Brunna) Recipharm Solna + Pharmatory Oy 2020-2021 edition + Haugesund + AGA Gas AB TALLINN Interchemie Werken De Adelaar Eesti Dupont Nutrition Norge AS NORWAY Bioactive Bone Substitutes Borregaard AS Cambrex Karlskoga AB Pfizer Health AB STOCKHOLM + PharmaEstica + Fermion Oy + Recipharm Strängnäs Tallinna Farmaatsiatehase AS Researched, Compiled and Produced by La Tene Maps , Station House, Shankill, Dublin 18, Ireland. Tel:: 353 12847914 Karmøy + Oy Woikoski Ab Paldiski Kevelt NovaMatrix AS Fresenius Kabi Norge AS RISE Research Institutes of Sweden AB Pronova Biopharma AS Ar+dena Södertälje AB Kokkola E: [email protected], W: www.latenemaps.com Recipharm Karlskoga AstraZeneca AB + BASF AS Oy Woikoski Ab Syntagon AB + Recipharm Stockholm AB Kuoipo NORWAY - Not Shown TPI Enterprises Limited AS Larvik Orion Oyj Florø Galena Pharma Oy EWOS AS Stavanger Vistin Pharma AS Strömstad Haapsalu Kirkwall Finvector Oy Ålesund Kragerø Tablettproduksjon AS UNITED KINGDOM - CHESHIRE Epax Norway AS Tippakoski 1. Allergan Biologics Ltd Nyköping MAP Medical Technologies Brattvåg STOCKHOLM 2. Eli Lilly & Company Ltd KD Norway AS Varkaus Apotek Produktion & Laboratorier AB Oy Woikoski Ab ESTONIA ICELAND - REYKJAVIK 3. Seqirus Vaccines Ltd Averøy Norrköping Not shown on Map Scrabster 4. Croda Europe Ltd Skretting AS Swedish Orphan Biovitrum AB Tampere Santen Oy 5. Thompson & Capper Ltd Alvotech hf. Overhalla Egersund Arendal Octapharma AB GPE Globalpharma Kinlochbervie 6. Pharmaserve North West Ltd Pharmaq AS Dimedium Ísaga - Linde Healthcare Karolinska Universitetssjukhuset Pärnu 7. Mexichem Fluor Ltd Flekkefjord Röntgenkliniken Corpus, TBD-Biodiscovery Tromsø Valneva Sweden AB Ísteka ehf. BASF Pharma Ltd 8. Teva Runcorn Biotec BetaGlucans AS Universitetssjukhuset PharmaSynth Landspítali Háskólasjúkrahús 9. Solvay Interox Ltd Myre Linköping Stornaway BioMar AS GE Healthcare AS Kristiansand Lochinver 10. Elanco Lyfis ehf. AGA Gas AB Acino Estonia 11. Medimmune (Astra Zenaca) SKAGERRAK Air Liquide Gas AB UK - LUTON AREA Nouryon Pulp & Performance Ullapool 10. Niche Generics Ltd Chemicals AB BELGIUM - ANTWERP AREA DENMARK - COPENHAGEN AREA DENMARK - HØRSHOLM AREA Natumin Pharma AB 11. Ransom Naturals Carls-Bergh Pharma + 1. Laboratoria Wolfs NV 1. Paramedical A/S 27. Alk-Abello A/S + Fraserburgh 12. Bristol Laboratories Ltd Cellmatrix AB 28. CytoVac A/S Skagen Göteborg Västervik Gairloch 13. GlaxoSmithKline 2. Laboratoria Smeets NV 2. Scanpharm A/S AstraZeneca AB 3. Tramedico NV 3. NCK A/S 29. Pharmexa A/S DCG Nordic AB 14. TEMAG Pharma Visby 4. Qualiphar 4. Novo Nordisk A/S 30. ParaTech A/S Hirtshals Peterhead UK - WATFORD AREA + 5. Pfizer 5. Solural Pharma ApS 31. Merial Norden A/S + Novo Nordisk A/S A 15. GE Healthcare Ltd 6. Purna Pharmaceuticals 6. LEO Pharma A/S 32. Chr. Hansen A/S Ventspils 16. Pharmaron 7. Alcon Laboratories (Novartis) 7. Region Hovedstadens Apotek 33. Tracer Pharma ApS 17. Pharmasure Ltd Enterobiotix Ltd 8. Novo Nordisk A/S x2 34. HB-Medical ApS behördlich 18. Mylan (Generics Ltd) BELGIUM - BRUSSELS AREA RIGA LATVIA 8. Novartis Pharma NV 9. Orthana Kemisk Fabrik A/S E GMP- / GDP- Aberdeen 10. AGC Biologics A/S Vet-Allergy Medpro Sia 1. Silvanols UK - WESTERN LONDON METROPOLITAN AREA 9. Catalent Belgium SA zertifiziert 11. AJ Vaccines A/S Danipharm A/S 2. Grindeks AS 19. Crescent Manufacturing Ltd 10. Plasma Industries Belgium Vepidan ApS ABC pharma AS YOUR CDMO FOR Mallaig 12. Xellia Pharmaceuticals ApS RIGA 3. Sia LMP 20. Pharmvit Ltd 11. Corden Pharma Brussels SA Rigas Farmaceitiska Fabrika 1-8 13. Biofac A/S Borgholm 4. Briz AS RUSSIA 21. Thame Laboratories (Syri Ltd) 12. Boiron SPRL GMP- / GDP- 14. H. Lundbeck A/S GMPack ApS KATTEGAT Strandmöllen AB S 22. Accord Healthcare Ltd 13. BetaPlus Pharma SA Pharmadan Olainfarm AS 5. Kalceks AS certified HAZARDOUS CHEMISTRY GlaxoSmithKline + 15. Azanta Danmark A/S 23. MSD Animal Health 14. Laboratoires Sterop NV A/S (Biofac) Halmstad 6. Unifarma 16. Syntese A/S Takeda Pharma A/S Kalmar 24. GlaxoSmithKline 15. Roche SA Himmerlands Grovvarer A/S Drug Manufacturing L.E.V. Ekstraktu rupnica 7. Aptiekas produkcija 17. Chr. Hansen A/S Argenta Ltd 25. Lupin Healthcare 16. Besins Belgium SA Svenska Örtmedicinska Generics Manufacturing 8. Northern Synthesis Oban + 18. Chr. Olesen Synthesis + DermaPharm A/S Liepaja Tayside Pharmaceuticals Ltd BBI Solutions 26. GlaxoSmithKline 17. Peptisyntha SA Institutet AB Contract Manufacturing 19. Boehringer Ingelheim Grenå 27. Noumed Life Sciences Limited 18. Eurogenerics SA Recipharm Höganäs AB API Manufacturing 19. Erfa Pharm SA 20. Contura International A/S Allergon AB behördlich UK - SOUTHWESTERN LONDON METROPOLITAN AREA Bavarian Nordic A/S Ängelholm 20. Galactic 21. Abbott Laboratories A/S Vaccines Manufacturing GMP- / GDP- Anstruther SSI Diagnostica A/S + Symbiosis Pharmaceutical Services Ltd 28. GlaxoSmithKline ChemVDENMARKet Pharma ApS + AB Cernelle Karlskrona 21. Labina S.A. 22. Stada Nordic ApS Nordia Pharmaceutical Co. Perstorp Speciality Veterinary Manufacturing C zertifiziert Cox Pharmaceutical Ltd Piramal Healthcare 29. Cox Pharmaceuticals 23. MSD Danmark ApS Natur-Drogeriet A/S Biogen (Fujifilm) Chemicals AB + Collagen Solutions Ltd 22. Meda Pharma SA + + Naturals/Herbal 30. Boehringer Ingelheim Animal Health 24. BASF A/S Pharma-Skan ApS SmartPractice Denmark ++ BioReliance Ltd (Merck) Macfarlan Smith Ltd 23. Eumedica Bifodan A/S ScanVet Animal Health Officially Edinburgh 31. Medpharm Limited Nutritionals 25. Elanco + Alk-Abello A/S 24. PolyPeptide S.A. BioVita A/S H. Lundbeck A/S Åhus Uab Ruvera Rumbol Products Ltd + Valneva CytoVac A/S GMP- / GDP- Dechra Veterinary Novo Nordisk A/S + 32. Alliance Medical Molecular Imaging 26. Mylan + I Ferring Pharmaceuticals AB Biotechnology Ltd 25. Zoetis Belgium SA DuPont Nutrition Croda Denmark A/S Pharmexa certified Capsugel (Lonza) 33. IPS Specials Ltd Holistica-Medica A/S BioGaia Production AB The Mentholatum Company Ltd + 26. Minakem High Potent SA Biosciences ApS NETHERLANDS - AMSTERDAM AREA Pharmacosmos A/S 1-18 SwePharm AB Klaipeda DSM Nutritional Products Ltd TC Biopharm Ltd UK - SOUTHERN LONDON METROPOLITAN AREA 27. Novadip Biosciences Fertin Pharma A/S Novo Nordisk A/S Skånes Universitetssjukhus Klinge Chemicals Ltd 1. Pronova Laboratories B.V. Vetrepharm A/S BASF A/S Takeda + KL Pharmaceutical Ltd 33. A. Nelson And Company Ltd + + 28. Promethera Biosciences GlaxoSmithKline 2. Vemedia Manufacturing B.V. Chr. Hansen A/S KOBENHAVN + T 34. Alliance Medical Radiopharmacy Ltd ZPD A/S Malmö BELGIUM - BRABANT AREA 3. Abbott Biologicals B.V. Charles River Fef Chem. Apotek Produktion & Laboratorier AB 35. Ainsworths Ltd Esbjerg Leo Pharma Biofac A/S Bioglan AB Arcinova Ltd 29. Will-Pharma Benelux SA 4. Dutch Farm International B.V. PK Chem. Campbeltown Salfarm Danmark GK Pharma ApS Galenica AB LITHUANIA Major Companies in Inset Areas 30. Ajinomoto Omnichem N.V 5. SUN Pharmaceutical Industries (Europe) PolyPeptide Laboratories AB UNITED Scanpharm A/S Novo QPharma AB Piramal Healthcare Ltd 31. UCB PHARMA S.A. 6. Kite Pharma EU B.V. Nordisk L VIC - Animal Health Pharma Nord ApS Rechon Life Science AB Bornholm AUSTRIA - VIENNA SWITZERLAND - ZURICH AREA 32. Cenexi 7. Sanquin Plasma Products B.V. Viminco A/S Merck Sharp & Dohme Ltd Weleda Ges.m.b.H. & Co KG 1. Helvepharm AG (Zentiva) Moskva KINGDOMKilco Ltd Aesica Pharmaceuticals 33. Eli Lilly 8. PharmaMatch B.V. (DK) (Moscow) Nicobrand Accord Healthcare Sterling Pharma Solutions Ltd. Kottas Pharma GmbH 2. Akorn AG Wasdell Manufacturing Limited 9. Wacker Biotech B.V. MacFarlan Smith Ltd BELGIUM - LIEGE AREA JemoPharm A/S
Load more

Recommended publications
  • In the United States District Court for the Eastern District of Pennsylvania ______: in Re Suboxone (Buprenorphine : Mdl No
    IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA __________________________________________ : IN RE SUBOXONE (BUPRENORPHINE : MDL NO. 2445 HYDROCHLORIDE AND NALOXONE) : 13-MD-2445 ANTITRUST LITIGATION : : THIS DOCUMENT RELATES TO:, : : Wisconsin, et al. v. Indivior Inc. et al. : Case No. 16-cv-5073 : __________________________________________: STATE OF WISCONSIN : By Attorney General Brad D. Schimel, et al. : : CIV. A. NO. 16-5073 Plaintiffs, : v. : : INDIVIOR INC. f/k/a RECKITT BENCKISER : PHARMACEUTICALS, INC., et al. : : Defendants. : __________________________________________: Goldberg, J. November 24, 2020 MEMORANDUM Defendant Reckitt Benckiser, Inc. (“Defendant”) manufactures Suboxone, a drug commonly used to combat opioid addiction.1 Suboxone previously came in tablet form, but in 2010, citing safety concerns, Defendant effectuated a change in the administration of this drug, switching from tablet to sublingual film. Various purchasers/consumers of Suboxone claimed that this switch was anticompetitive and solely designed to maintain Defendant’s market exclusivity—a scheme known as a “product hop.” These claims have resulted in multi-district, antitrust litigation before this Court. 1 Reckitt is currently known as Indivior, Inc. In December 2014, Reckitt Benckiser Pharmaceuticals, Inc. was demerged from its prior parent, the Reckitt Benckiser Group PLC, into Indivior PLC. Although Indivior is technically the named defendant in this case, the pleadings and many of the relevant exhibits use the name “Reckitt.” As discovery and class certification litigation have come to a close, the parties have raised numerous challenges under Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993), seeking exclusion of all or selected portions of nine expert witnesses anticipated opinions. This Opinion explains my reasoning for the resolution of these motions and will hopefully set forth a clearer path towards trial.
    [Show full text]
  • FREDERICK ('ERIC') RANDALL SMITH Bsc, Phd(Edin), FRSC Eric
    FREDERICK ('ERIC') RANDALL SMITH BSc, PhD(Edin), FRSC Eric Smith was responsible for research activities in Duncan Flockhart Ltd, T & H Smith Ltd and Edinburgh Pharmaceutical Industries Ltd during the period 1947 to 1971. He and his colleagues made several lasting contributions to medicine and commerce notable amongst which were the creation of a new opiate industry based on large scale poppy growing in Australia, the establishment of dihydrocodeine ('DF118') as a major analgesic, and the discovery of 'Bitrex', an intensely bitter substance, now a widely used denaturant. He was elected a Fellow of the Society in 1962 and served on Council 1969-71. Born in Edinburgh on April 4th, 1911, Eric spent his childhood, his school and university days, and most of his working life and retirement in or near to the City. He died there on November 4th, 1994. Eric's enquiring attitude to life owed much to his father. This unusual man earned his living in the Actuarial Department of the Scottish Provident Institution but his main interests were astronomy and art. He was an FRAS and his personal observations led to his name being given to a minor lunar crater, and a good enough artist for his works to be hung in the Royal Academies in Edinburgh and London. Perhaps this is why Eric chose to be a scientist and his sister an art teacher. Eric was educated at the Edinburgh Institution (later named Melville College) where he was an excellent scholar and a good enough sportsman to play for the 1st XV and the FPs.
    [Show full text]
  • Effects of Supplementary Protection Mechanisms for Pharmaceutical Products
    Final report, May 2018 Effects of supplementary protection mechanisms for pharmaceutical products www.technopolis-group.com Effects of supplementary protection mechanisms for pharmaceutical products technopolis |group| May 2018 Thyra de Jongh* Alfred Radauer Sven Bostyn Joost Poort * Corresponding author. [email protected] About the authors Thyra de Jongh PhD, is a Senior Consultant Health & Life Sciences at Technopolis Group in Amsterdam. She specialises in analysis of health systems and policies, and research and innovation in the health and life sciences. She has a particular interest in pharmaceutical innovation and access to medicine. (thyra.dejongh@technopolis- group.com) Alfred Radauer, is Senior Consultant at Technopolis Group in Vienna and leads the Intellectual Property & Standards (IPS) group within Technopolis. His and the IPS group work elaborate on the interfaces between legal, technological and economic issues of IP and standards in innovation policy as well as the interaction of IP with regulation and other policy areas. ([email protected]) Sven Bostyn Lic.Jur, LL.M, PhD, is a senior lecturer in Intellectual Property Law at the University of Liverpool Law School. He is also an assistant professor at the Institute for Information Law, University of Amsterdam. He is one of the leading experts in Europe in patent law and related subjects in the areas of life sciences and pharmaceutical inventions, and has more than sixty single-authored publications. ([email protected]) Joost Poort PhD, is an associate professor in economics at the Institute for Information law, University of Amsterdam. He brings an economic perspective to various multidisciplinary research projects, with particular interest in intellectual property.
    [Show full text]
  • List of Tuberculosis Pharmaceutical Products Classified According to the Global Fund Quality Assurance Policy
    List Of Tuberculosis Pharmaceutical Products classified according to the Global Fund Quality Assurance Policy Edition: Version 104 - 14 July 2021 The list is an overview of pharmaceutical products subject to the Global Fund Quality Assurance Policy that are listed in National and/or WHO standard treatment guidelines and classified according to the various options (A, B, and ERP reviewed) defined in the Global Fund Quality Assurance Policy (July 2009, amended in December 2010). The list is developed as a tool to assist Principal Recipients (PR) of Global Fund grants to identify the status of finished pharmaceutical products according to the Global Fund Quality Assurance Policy. The pharmaceutical products are classified based on the following information A classified product - Listed on WHO prequalification list; B classified product - Stringent NDRA Registration letter/Marketing Authorization; ERP reviewed product- Permitted for time-limited procurement based on advice by the Expert Review Panel (ERP); Please note that the list is not an exhaustive list. A PR can procure product(s) not listed in the current list as long as PR demonstrates that the product is compliant with the Global Fund Quality Assurance Policy. The Global Fund list includes the following information: - "Important Notes" for helpful information; - A, B, and ERP reviewed products; - Period validity of the ERP reviewed products; - "+" means combination product, both fixed-dose combination (co-formulated) and co-packaged product ( i.e. co-blister) - [A+B]+C means A and B are in fixed-dose formulation and C is co-packaged YELLOW signifies a new entry; PINK signifies modification of an existing entry.
    [Show full text]
  • Morphinone Reductase for the Preparation Of
    Europäisches Patentamt *EP000649465B1* (19) European Patent Office Office européen des brevets (11) EP 0 649 465 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C12N 9/02, C12P 17/18, of the grant of the patent: C12Q 1/32 24.07.2002 Bulletin 2002/30 (86) International application number: (21) Application number: 93913236.1 PCT/GB93/01129 (22) Date of filing: 28.05.1993 (87) International publication number: WO 94/00565 (06.01.1994 Gazette 1994/02) (54) MORPHINONE REDUCTASE FOR THE PREPARATION OF HYDROMORPHONE AND HYDROCODONE MORPHINONE REDUKTASE ZUR HERSTELLUNG VON HYDROMORPHONE UND HYDROCODONE MORPHINONE REDUCTASE DESTINEE A LA PREPARATION D’HYDROMORPHONE ET D’HYDROCODONE (84) Designated Contracting States: (74) Representative: Perry, Robert Edward AT BE CH DE DK ES FR GB IE IT LI NL PT SE GILL JENNINGS & EVERY Broadgate House (30) Priority: 25.06.1992 GB 9213524 7 Eldon Street London EC2M 7LH (GB) (43) Date of publication of application: 26.04.1995 Bulletin 1995/17 (56) References cited: WO-A-90/13634 (73) Proprietor: MACFARLAN SMITH LIMITED Edinburgh EH11 2QA (GB) • THE BIOCHEMICAL JOURNAL vol. 274, no. 3, 15 March 1991, pages 875 - 880 NEIL C. BRUCE ET (72) Inventors: AL. ’Microbial degradation of the morphine • HAILES, Anne, Maria 59 Lower Road alkaloids. Purification and characterization of Kent DA8 1AY (GB) morphine dehydrogenase from Pseudomonas • FRENCH, Christopher, Edward putida M10’ Palmerston North (NZ) • BRUCE, Neil, Charles Cambridge CB2 1ND (GB) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Points of Excellence
    POINTS OF EXCELLENCE www.rtu.lv Riga Technical University, 2016 Published by: International Relations Department Design and layout: Arnis Grinbergs Photo credits: Arturs Pērkons, Eduards Lapsa, Edgars Špengelis, Aleksandrs Kendenkovs, Andris Eglītis, Jānis Knāķis, Edijs Pālēns / LETA, Imants Urtāns, Valts Kleins POINTS OF EXCELLENCE 6 Riga Technical University (RTU) – Strategic Partner for Excellence 72 Riga Business School 8 Latvia and Riga – “Added Value” of RTU 73 BALTECH Study Center 10 The Republic of Latvia 74 Affiliations 14 The Capital City – Riga 75 Engineering High School 20 History of RTU 76 Research at RTU 28 RTU in the 21st Century 77 Research Management 30 RTU Ķīpsala Campus 78 Research platforms and main research areas 36 RTU Structure 80 Selected Research Projects 39 RTU Strategy 94 Cooperation with Enterprises 40 Studies at RTU 95 Start-Up and Spin-Off Enterprises 40 Study Process Management 96 Business Incubators 42 Faculty of Architecture and Urban Planning 98 Design Factory 46 Faculty of Civil Engineering 100 Scientific Library 48 Faculty of Computer Science and Information Technology 104 Student Parliament 50 Faculty of Electronics and Telecommunications 106 International Relations CONTENTS 54 Faculty of Power and Electrical Engineering 116 Sports 58 Faculty of E-Learning Technologies and Humanities 120 Culture 60 Faculty of Engineering Economics and Management 128 RTU Alumni Association 64 Faculty of Materials Science and Applied Chemistry 136 RTU Contacts 68 Faculty of Mechanical Engineering, Transport and Aeronautics niversity should not just react at Despite a marked focus on engineering, we pay changes in the society; it should be the much attention to sports and cultural activities – driving force for change! Riga Technical RTU teams in basketball, volleyball and floorball University adheres to this principle in have won medals in both Latvian and European Uthe field of tertiary education and is constantly championships.
    [Show full text]
  • ESG Report 2018
    JSC Olainfarm ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2018 Report is based on Guidelines of NASDAQ ESG Guide for Nordic and Baltic Markets ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2018 Start of financial year: 1 January 2018 End of financial year: 31 December 2018 Company name: Joint Stock Company Olainfarm Unified registration No. 40003007246 Address and contacts: Olaine Municipality, Olaine, 5 Rupnicu Street, LV-2114, Latvia (+371) 67013705 E-mail: [email protected] Chairman of the Board: Lauris Macijevskis Area of business: Pharmacology Website: www.olainfarm.com Auditing company: LLC PricewaterhouseCoopers Shares of JSC Olainfarm are listed at Nasdaq Riga Ocial List (ISIN:LV0000100501, ID: OLF1R) ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2018 Table of Contents 5 15 37 Company Environmental Quality management • Mission, Vision and Main Tasks 5 Responsibility • Shareholders 7 • Finished Dosage Forms, Active • Environmental Policy and Regulating Pharmaceutical Ingredients and Documents 16 40 Intermediates 7 • Control of Greenhouse Gas Emissions 17 • Largest Subsidiaries 7 Corporate governance • Employees 8 • Management of Environmental Risks 18 • Representation of Interests 8 • Monitoring of Environmental Risks 19 • Responsible Business Environment and • Packaging Policy 25 Cooperation with NGOs 41 • Waste Management 25 • Responsible Board 41 • Recycled Materials 28 - Obligations and responsibility 9 of the Board - Composition of the Board and Chairman’s 29 Requirements to Members of the Board - Transparent work of the board
    [Show full text]
  • Copyright Notice
    www.generics-bulletin.com Bulletin Publishing Group 4 Poplar Road, Dorridge, Solihull B93 8DB, UK Tel: +44 (0)1564 777550 Fax: +44 (0)1564 777524 E-mail: [email protected] COPYRIGHT NOTICE This publication must not be forwarded, exported, distributed or circulated by any means or in any format to persons including clients outside the direct employment of your Company. You may distribute the publication internally, but you may incorporate only insubstantial extracts, abstractsbulletin or summaries into presentations, providing Generics is identified as the source of the information. bulletin bulletin The publication/s, Generics and/or News@Generics , in PDF and/or HTML format, are supplied to you strictly under the terms and conditions of the Global Licence agreement between your Company and OTC Publications Ltd, the copyright holder of the publications. The publication/s are the intellectual property of the Publisher, OTC Publications Ltd and are protected by English copyright, trademark and other laws. Bulletin Publishing Group is a division of OTC Publications Ltd Registered Office: 4 Poplar Road, Dorridge, Solihull B93 8DB, UK. Registered in England No 2765878 Gen 18/4/14 Pg. 1_Gen 18/11/05 Pg. 1 15/04/2014 20:12 Page 1 18 April 2014 COMPANY NEWS 2 Sun makes US$4 billion Mylan misses out on 2 move to gain Meda Pamplona fund takes control of Alvogen 3 Bioton benefits as sales 4 bid to snap up Ranbaxy of insulin boom Sun seeks synergies from Ranbaxy deal 5 un Pharmaceutical Industries intends to create the world’s fifth-largest generics player, Latvia’sOlainfarm sees 6 Sand India’s leading pharma company,bypaying around US$4.0 billion forits rival, upside to crisis Ranbaxy.The deal comprises US$3.2 billion of equity,and US$800 million of assumed debt.
    [Show full text]
  • Audited Country Address Product Type Audit Date Audit Format
    AZBIL TELSTAR TECHNOLOGIES, S.L.U. www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 Audited Country Address Product type Audit Date Audit Format SOLARA ACTIVE PHARMA R. S. No. 33 & 34, Mathur Road, SCIENCES LIMITED (antes India Periyakalapet, Puducherry, IN- API 4-Jan-2019 1d/1a+CAPA STRIDES SHASUN LIMITED) 605 014 India PLOT NO. E-22 M.I.D.C. Tarapur, AARTI DRUGS LTD. India Tal. Palghar, District Thane, 401 API 3-Jul-2019 1d/1a+CAPA 506, Tarapur, Maharashtra. India SOLARA ACTIVE PHARMA R. S. No. 33 & 34, Mathur Road, SCIENCES LIMITED (antes India Periyakalapet, Puducherry, IN- API 4-Jan-2019 1d/1a+CAPA STRIDES SHASUN LIMITED) 605 014 India PLOT NO. E-22 M.I.D.C. Tarapur, AARTI DRUGS LTD. India Tal. Palghar, District Thane, 401 API 3-Jul-2019 1d/1a+CAPA 506, Tarapur, Maharashtra. India Carrer Radi, 08755 Castellbisbal, OLMED SPAIN OTROS 10-May-2017 1d/1a+CAPA Barcelona Plot No. W-60(B), 61 (B), 62(B), 71 (B), 72(B), 73(B), M.I.D.C. AARTI DRUGS LTD. India API 5-Jul-2019 1d/1a+CAPA Taranpur, Boisar, Dist. Thane, Maharashtra 401506 INDIA Audit Reports_January 2020 AZBIL TELSTAR TECHNOLOGIES, S.L.U. www.telstar-lifesciences.com Tel/Fax: +34 937 361 600 / +34 937 861 380 Plot No. W 71(B) & 72(B) M.I.D.C. Tarapur, Tal. Palghar, District AARTI DRUGS LTD. India API 20-Jun-2018 1d/1a+CAPA Thane, India-401 506 Tarapur, Maharashtra - India Plot No. W 71(B) & 72(B) M.I.D.C.
    [Show full text]
  • Analysis of the Global Fund Financed Market for TB Medicines: Competitive Landscape, Market Shares, Product Volumes and Product Variety
    Fall 08 2014 Analysis of the Global Fund Financed Market for TB Medicines: Competitive landscape, market shares, product volumes and product variety Lisa Smith & Prashant Yadav January 2014 1 Acknowledgements This analysis was possible mainly due to the publicly available transaction data in the Price, Quality and Reporting database of the Global Fund to Fight AIDS, Tuberculosis & Malaria. The authors would like to thank all associated with conceptualizing, developing, designing and improving this database. In addition, the authors would like to acknowledge support from UNITAID to understand the market for TB drugs. Disclaimer All errors of fact, logic, assumption, and judgment are only those of the authors and should not be attributed to the sources of data or the institutions or individuals listed earlier. The analysis and views expressed in this report are those of the authors and do not necessarily reflect those of the management or the funders of the William Davidson Institute. 2 Table of Contents BACKGROUND 4 PRODUCT MARKET ANALYSIS 7 FIRST-LINE DRUGS 7 ETHAMBUTOL + ISONIAZID – FIXED DOSE COMBINATION 7 ETHAMBUTOL + ISONIAZID + PYRAZINAMIDE + RIFAMPICIN – FIXED DOSE COMBINATION 7 ETHAMBUTOL + ISONIAZID + RIFAMPICIN – FIXED DOSE COMBINATION 11 ISONIAZID + PYRAZINAMIDE + RIFAMPICIN – FIXED DOSE COMBINATION, DISPERSIBLE 13 ISONIAZID + RIFAMPICIN 16 SECOND-LINE DRUGS 25 INJECTABLES AGENTS 25 AMIKACIN 25 CAPREOMYCIN 26 KANAMYCIN 29 STREPTOMYCIN 32 FLUOROQUINOLONES 35 LEVOFLOXACIN 35 MOXIFLOXACIN 38 ORAL BACTERIOSTATIC SECOND-LINE AGENTS 41 CYCLOSERINE 41 PARA-AMINOSALICYLIC ACID (PAS) AND PAS SODIUM 43 PROTHIONAMIDE 47 TUBERCULOSIS TREATMENT KITS 48 SINGLE SUPPLY MARKETS 50 SINGLE SUPPLIER PRODUCT MARKETS – 2011 50 SINGLE SUPPLIER PRODUCT MARKETS – 2012 51 SINGLE SUPPLIER PRODUCT MARKETS – 2011/2012 52 3 Background Ensuring consistent access to affordable, quality tuberculosis (TB) medications remains a key focus area in global health.
    [Show full text]
  • United States Securities and Exchange Commission Form 10-K Shire Pharmaceuticals Group
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ፤ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 អ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 0-29630 SHIRE PHARMACEUTICALS GROUP PLC (Exact name of registrant as specified in its charter) England and Wales (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) N.A. East Anton, Andover, Hampshire SP10 5RG England (Address of principal executive offices) (Zip Code) 44 1264 333455 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of exchange on which registered American Depository Shares, each representing Nasdaq National Market 3 Ordinary Shares, 5 pence nominal value per share Securities registered pursuant to Section 12(g) of the Act: None (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ፤ No អ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the Registrant's knowledge, in definitive proxy or information statements incorporated by reference to Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • August/September 2016
    INTERNATIONAL PHARMACEUTICAL QUALITY IPQ Inside the Global Regulatory Dialogue IPQPUBS.COM VOL. 8, NO. 5 MONTHLY UPDATE - AUGUST/SEPTEMBER 2016 UNITED STATES ● Review/Inspection Control Strategy Communications Key to Advancing Biotech p. 4 Regulation, FDA Biotech Official Stresses ● More Clarity Sought in FDA’s Inactive Ingredient Database Regarding Drug Delivery Devices p. 13 EUROPE ● Protein Sequence Variants, Process Development and Spec Setting Are Generating Queries p. 20 from EU Biopharmaceutical CMC Assessors ● Procedures, Eligibilities and Goals of EMA’s Accelerated Access Efforts Are Taking More p. 32 Concrete Shape INTERNATIONAL ● Goal of FDA/EU Mutual Inspection Reliance is Nearing Realization p. 36 UPDATES IN BRIEF p. 47 U.S. CMC: ● GDUFA II Agreement ● ANDA Impurity Refusals ● Capsule Supplier Changes ● Co-Crystal Classification ● ANDA Impurity Refusals U.S. GMP: ● Insanitary Compounding ● NIH Clinical Manufacturing ● Establishment Registration ● Generics Facility ID'ing ● USP on Analytical Lifecycles EUROPE CMC: ● EMA Streamlining ● EMA Adaptive Pathways Workshop ● EDQM on ICH Q3D EUROPE GMP: ● EMA WFI Q&A ● EC on Plastics INTERNATIONAL CMC: ● Antimicrobial Resistance Roadmap ● WHO on Variations ● Canada on ICH Q3D INTERNATIONAL GMP: ● China on Drug Manufacturing ● India Manufacturing Self-Assessment FDA WARNING LETTERS, EMA NON-COMPLIANCE REPORTS, AND FDA RECALLS POSTED IN AUGUST/SEPTEMBER p. 51 MONTHLY UPDATE - AUGUST / SEPTEMBER 2016 INTERNATIONAL PHARMACEUTICAL QUALITY provides in-depth coverage of emerging drug, biologic and combination product CMC and GMP issues and developments with a mission of helping advance and harmonize the quality regulatory process globally. Headquartered in Washington, D.C., IPQ is read by regulatory agencies, manufacturers, suppliers, consultants, law firms, and universities around the world.
    [Show full text]